Replicative minicircle vectors with improved expression

Inventors

Williams, James A.

Assignees

Aldevron LLC

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10047365-B2

Patent

Publication Date

2018-08-14

Expiration Date


Abstract

The present invention relates to the production and use of covalently closed circular (ccc) recombinant DNA molecules such as plasmids, cosmids, bacterial artificial chromosomes (BACs), bacteriophages, viral vectors and hybrids thereof, and more particularly to vector modifications that improve expression of these DNA molecules.

Core Innovation

The invention describes constructing a eukaryotic replicative pUC-free minicircle expression vector. The vector comprises a eukaryotic region encoding a transgene of interest and a spacer region of less than 500 base pairs linking the 5′ and 3′ ends of the eukaryotic region. This spacer comprises a bacterial region containing an R6K bacterial replication origin and an RNA-OUT selectable marker.

The vector is introduced into a target eukaryotic cell or an organism comprising that cell to transfect the cell. The transgene is expressed at a higher level than from a minicircle vector with a spacer region greater than 500 base pairs or a pUC origin. Furthermore, the vector configuration supports high-yield manufacture for gene therapy, genetic immunization, and therapeutic expression.

Claims Coverage

The claims identify one independent claim covering the construction and use of a eukaryotic replicative pUC-free minicircle expression vector, comprising three inventive features.

Compact bacterial spacer region

The spacer region is less than 500 base pairs in length, links the 5′ and 3′ ends of the eukaryotic region, and comprises a bacterial region with an R6K bacterial replication origin and an RNA-OUT selectable marker.

Transgene-containing eukaryotic region

The vector comprises a eukaryotic region encoding a transgene of interest, combined with the spacer region to create a eukaryotic replicative pUC-free minicircle expression vector.

Transgene expression in a target eukaryotic cell

The vector is introduced into a target eukaryotic cell, or an organism comprising that cell, under conditions wherein the cell is transfected and the transgene is expressed at a higher level than from a minicircle vector comprising a spacer region greater than 500 base pairs or a pUC origin.

The claim centers on a compact pUC-free minicircle architecture containing an R6K replication origin and RNA-OUT selectable marker, and on introducing the vector into a target eukaryotic cell for enhanced transgene expression relative to comparator vectors.

Stated Advantages

The vectors show improved in vivo transgene expression over larger-spacer or pUC-origin comparators, with up to 5.3–6.3-fold higher expression reported for NTC9385R after intradermal delivery.

The reported fermentation yields are 184–745 mg/L, supporting high-yield manufacture.

Intronic and 3′ UTR configurations retain expression and plasmid quality, and gel analysis reveals no detected replication intermediates.

Documented Applications

Expression of a growth-factor transgene for gene therapy.

Expression of a therapeutic-antibody transgene to neutralize an infectious disease.

Expression of a target-antigen transgene for genetic immunization.

Therapeutic expression.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.